Subtype
Malignant Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001179Explore in graph →
66 active trials2 approved drugs25 evidence items
- NCIt
- C6588
Loading cancer entity…
Subtype
CI-CAN-00001179Explore in graph →
Clinical trials
186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT04906876 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
| withdrawn |
| Phase 2 |
| 0 |
| Brown UniversityOTHER |
| 1 |
| Jul 28, 2021 |
| clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | withdrawn | Phase 3 | 0 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01795430 | Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2025source: clinicaltrials